GENinCode PLC - Result of GM, Director Shareholdings and TVR
GENinCode Plc
("GENinCode" or the "Company")
Result of General Meeting, Director Shareholdings and Total Voting Rights
GENinCode plc (AIM: GENI), the polygenics company focused on the prevention of cardiovascular disease ("CVD") and risk assessment of ovarian cancer, announces that all resolutions put to Shareholders at the General Meeting held earlier today in connection with the placing, subscription and retail offer announced by the Company on
|
Resolution |
For |
Against |
Withheld |
Total votes cast |
|||
|
|
|
Number of votes |
% |
Number of votes |
% |
Number of votes |
|
|
1 |
Ordinary resolution to authorise the directors to allot shares |
143,609,162 |
99.99% |
17,570 |
0.01% |
7,500 |
143,626,732 |
|
2 |
Special resolution to authorise the directors to disapply pre-emption rights |
143,604,972 |
99.98% |
21,760 |
0.02% |
7,500 |
143,626,732 |
(1) Any proxy appointments, which gave discretion to the Chairman have been included in the 'For' votes total.
(2) Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.
(3) A vote "Withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against", nor in the aggregate figure of total votes cast.
Director Shareholdings
The following Directors subscribed for New Ordinary Shares pursuant to the Fundraising. The number of New Ordinary Shares subscribed for by each Director and their resulting shareholdings upon Admission are set out below:
|
Name |
Number of existing Ordinary Shares |
Percentage of Existing Issued Share Capital |
Number of Subscription Shares allocated (1) |
Number of Ordinary Shares held following Admission |
Percentage of Enlarged Share Capital following Admission |
|
|
14,737,636 |
5.14% |
500,000 |
15,237,636 |
2.0% |
|
|
12,235,473 |
4.26% |
2,000,000 |
14,235,473 |
1.9% |
|
|
7,417,243 |
2.59% |
17,500,000 |
24,917,243 |
3.3% |
|
|
1,273,587 |
0.44% |
1,500,000 |
2,773,587 |
0.4% |
|
|
905,405 |
0.32% |
1,000,000 |
1,905,405 |
0.3% |
|
|
100,000 |
0.03% |
500,000 |
600,000 |
0.1% |
|
|
|
|
|
|
|
(1) The number of Ordinary Shares presented in this table as being held or subscribed for by Directors refers to the number of Ordinary Shares held or subscribed for by them either personally or through a nominee.
(2) Paul Foulger participating through the Placing and includes Ordinary Shares held by Laura Deegan, Paul Foulger's wife.
(3) Includes Ordinary Shares held by Sonia Rodriguez Clemente, Jordi Puig's wife.
(4) Includes shares held by Marion Gray, Huon Gray's wife.
The notifications below, made in accordance with the requirements of the UK Market Abuse Regulation, provide further details.
Admission and Total Voting Rights
Following shareholder approval at the general meeting and conditional on admission, a total of 466,159,095 new Ordinary Shares (comprising 300,800,000 Placing Shares, 87,345,000 Subscription Shares, 58,000,000 Additional Subscription Shares and 20,014,095 Retail Shares will be admitted to trading on AIM ("Admission") at
Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 753,041,137 with each Ordinary Share carrying the right to one vote. There are no shares held in treasury and therefore, following Admission, the total number of voting rights in the Company will be 753,041,137.
The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules.
Capitalised terms used in this announcement have the meaning given to them in the announcement dated
Enquiries:
|
GENinCode Plc |
www.genincode.com or via Walbrook PR |
|
Matthew Walls, CEO |
|
|
|
|
|
Cavendish Capital Markets Limited (Nomad, Broker and Joint Bookrunner) |
Tel: +44 (0) 20 7220 0500 |
|
Giles Balleny / Trisyia Jamaludin (Corporate Finance) Nigel Birks (Life Sciences Specialist Sales) Harriet Ward (Corporate Broking) Dale Bellis / Michael Johnson (Sales)
|
|
|
Oberon Capital (Joint Bookrunner) Mike Seabrook / Adam Pollock / Aimee McCusker
|
Tel: +44 (0) 203 179 5300 |
|
Turner Pope Investments (TPI) Ltd (Joint Bookrunner) Guy McDougall / Andy Thacker |
Tel: (0) 20 3657 0050 |
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or |
|
Anna Dunphy |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||||||||||||||||||||
|
a) |
Name |
1. Jordi Puig 2. Matthew Walls 3. Sergio Olivero 4. Paul Foulger 5. Huon Gray 6. Felix Freuh
|
|||||||||||||||||||||
|
2 |
Reason for the notification |
||||||||||||||||||||||
|
a) |
Position/status |
1. Chief Operations Officer 2. Chief Executive Officer 3. Non-Executive Director 4. Chief Financial Officer 5. Non-Executive Director 6. Non-Executive Director |
|||||||||||||||||||||
|
b) |
Initial notification /Amendment |
Initial notification |
|||||||||||||||||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||||||||||||||
|
a) |
Name |
GENinCode Plc |
|||||||||||||||||||||
|
b) |
LEI |
213800UX6TE7K65O2892 |
|||||||||||||||||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||||||||||||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of
GB00BL97B504 |
|||||||||||||||||||||
|
b) |
Nature of the transaction |
1,2,3,5,6: Subscription for New Ordinary Shares 4: Subscription for New Ordinary Shares through Placing |
|||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
|||||||||||||||||||||
|
d)
|
Aggregated information - Aggregated volume - Price |
n/a - single transaction |
|||||||||||||||||||||
|
e) |
Date of the transaction |
|
|||||||||||||||||||||
|
f) |
Place of the transaction |
Outside a trading venue
|
|||||||||||||||||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE